Clinical Trial Update: Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1 [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating insulin-like growth factor-1 for growth failure in X-linked severe combined immunodeficiency (X-SCID) was terminated; results were po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Failure
• Growth Hormone Resistance
• X-linked Severe Combined Immunodeficiency

Drugs mentioned

• INCRELEX (Mecasermin)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID) | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2015-07-03